Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non–Muscle-invasive Bladder Cancer

• Published in: European urology Vol. 69; no. 6; pp. 1046 - 1052
• Main Authors: Arends, Tom J.H, Nativ, Ofer, Maffezzini, Massimo, de Cobelli, Ottavio, Canepa, Giorgio, Verweij, Fabrizio, Moskovitz, Boaz, van der Heijden, Antoine G, Witjes, J. Alfred
• Format: Journal Article
• Language: English
• Published: Switzerland Elsevier B.V 01.06.2016
• Subjects: Adjuvants, Immunologic - therapeutic use; Administration, Intravesical; Aged; Antibiotics, Antineoplastic - therapeutic use; BCG; BCG Vaccine - therapeutic use; Carcinoma in Situ - pathology; Carcinoma in Situ - therapy; Carcinoma, Papillary - pathology; Carcinoma, Papillary - therapy; Combined Modality Therapy; Device-assisted therapy; Disease Progression; Disease-Free Survival; Female; Humans; Hyperthermia; Hyperthermia, Induced; Intravesical chemotherapy; Male; Middle Aged; Mitomycin - therapeutic use; Mitomycin-C; Muscle, Smooth - pathology; Neoplasm Invasiveness; Non–muscle-invasive bladder cancer; Prospective Studies; Radiofrequency; Randomised controlled trial; Recurrence rate; Risk Factors; Thermochemotherapy; Urinary Bladder Neoplasms - pathology; Urinary Bladder Neoplasms - therapy; Urology; Thermochemotherapy; Non–muscle-invasive bladder cancer; Device-assisted therapy; Intravesical chemotherapy; BCG; Randomised controlled trial; Mitomycin-C; Radiofrequency; Recurrence rate; Hyperthermia
• ISSN: 0302-2838; 1873-7560
• DOI: 10.1016/j.eururo.2016.01.006

Abstract Background Despite adjuvant intravesical therapy, recurrences in non–muscle-invasive bladder cancer (NMIBC) are still high; therefore, new treatment options are needed. The use of chemohyperthermia (CHT) as an alternative treatment is expanding in Europe. To date, however, there has been a lack of prospective randomised data. Objective To compare CHT using mitomycin C (MMC) with bacillus Calmette-Guérin (BCG) as adjuvant treatment for intermediate- and high-risk NMIBC. Design, setting, and participants Between 2002 and 2012, 190 NMIBC patients were randomised in this controlled, open-label, multicentre trial for 1-yr CHT (six weekly treatments and six maintenance treatments) and 1-yr BCG immunotherapy (six weekly treatments and three weekly maintenance treatments at months 3, 6, and 12). Patients and physicians giving the interventions were aware of assignment. This study is registered with ClinicalTrials.gov ( NCT00384891 ). Outcome measurements and statistical analysis The primary end point was 24-mo recurrence-free survival (RFS) in the intention-to-treat (ITT) and per-protocol (PP) analyses in all papillary NMIBC patients ( n = 147). Analyses were done with the log-rank test and Fisher exact test. All tests were two-sided. Results and limitations The 24-mo ITT RFS was 78.1% in the CHT group compared with 64.8% in the BCG group ( p = 0.08). The 24-mo RFS in the PP analysis was 81.8% in the CHT group compared with 64.8% in the BCG group ( p = 0.02). Progression rates were <2% in both groups. Regarding the side-effects, no new safety concerns were identified. A concern is that this study closed prematurely and thus is underpowered. Furthermore, blinding of treatment for patients and physicians was impossible; this may have resulted in unavoidable bias. Conclusions CHT is a safe and effective treatment option in patients with intermediate- and high-risk papillary NMIBC. A significantly higher 24-mo RFS in the CHT group was seen in the PP analysis. Based on the results above, CHT is an option for BCG therapy as adjuvant treatment for intermediate- and high-risk papillary NMIBC. Patient summary Recurrences in non–muscle-invasive bladder cancer are common, despite adjuvant therapies. We compared 24-mo recurrence-free survival (RFS) with chemohyperthermia (CHT) versus bacillus Calmette-Guérin (BCG) therapy. According to these data, CHT therapy appears to be safe and has higher 24-mo RFS than BCG therapy.